why choose us

First received: June 08, 2023

Clinical Trial: A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Healthy

Study Type: INTERVENTIONAL


Official Title: Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Single Dose Selpercatinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Brief Summary: The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants.This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants.This study will last up to approximately 26 days excluding screening period.

Read more